AI Article Synopsis
- Agonistic anti-CD40 antibodies effectively boost anti-tumor immune responses by influencing both immune and tumor cells, enhancing dendritic cell function to stimulate cytotoxic T-cell activity.
- These antibodies are considered ideal for combining with traditional cancer treatments, like chemotherapy and surgery, to enhance immune-mediated attacks on tumors.
- The review discusses the mechanisms of agonistic anti-CD40, experiments using mouse models, and ongoing clinical trials that involve its integration with chemotherapy and other immunotherapies in humans.
Article Abstract
Agonistic anti-CD40 antibody is a potent stimulator of anti-tumor immune responses due to its action on both immune and tumor cells. It has the ability to "precondition" dendritic cells, allowing them to prime effective cytotoxic T-cell responses. Thus, anti-CD40 antibody provides an ideal therapy for combination with traditional cancer treatments (i.e., chemotherapy, surgery) in order to elicit immune-mediated anti-tumor effects. This review summarizes the mechanisms of action of agonistic anti-CD40, the use of mouse models to investigate its effects and combinations with other therapies in vivo, and current clinical trials combining humanized anti-CD40 antibody with chemotherapy and/or other immunotherapies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/08830185.2012.698338 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!